Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: REGN
  • CUSIP: 75886F10
Key Metrics:
  • Previous Close: $405.25
  • 50 Day Moving Average: $401.82
  • 200 Day Moving Average: $388.36
  • Trailing P/E Ratio: 63.22
  • Foreward P/E Ratio: 28.08
  • P/E Growth: 2.05
  • Market Cap: $42.40B
  • Outstanding Shares: 104,633,000
  • Beta: 1.08
Additional Links:
Companies Related to Regeneron Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) (?)
Ratings Breakdown: 1 Sell Rating, 12 Hold Ratings, 11 Buy Ratings
Consensus Rating:Hold (Score: 2.42)
Consensus Price Target: $477.43 (17.81% upside)

Analysts' Ratings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateFirmActionRatingPrice TargetDetails
8/17/2016Jefferies GroupReiterated RatingHoldView Rating Details
8/10/2016Goldman Sachs Group Inc.Reiterated RatingBuyView Rating Details
8/6/2016Leerink SwannSet Price TargetBuy$530.00 -> $511.00View Rating Details
8/6/2016RBC Capital MarketsReiterated RatingBuyView Rating Details
8/5/2016Roth CapitalReiterated RatingBuy$520.00View Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00View Rating Details
8/5/2016Canaccord GenuityReiterated RatingHold$450.00View Rating Details
8/5/2016Robert W. BairdDowngradeOutperform -> Neutral$505.00 -> $448.00View Rating Details
8/5/2016Cowen and CompanyReiterated RatingHold$430.00View Rating Details
7/12/2016BTIG ResearchReiterated RatingHoldView Rating Details
6/30/2016Sanford C. BernsteinReiterated RatingBuyView Rating Details
6/23/2016Citigroup Inc.Reiterated RatingBuy$470.00View Rating Details
6/8/2016Chardan CapitalDowngradeSell$325.00View Rating Details
6/8/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details
6/6/2016Piper Jaffray Cos.Reiterated RatingHoldView Rating Details
4/8/2016Morgan StanleyLower Price Target$436.00 -> $415.00View Rating Details
4/1/2016Credit Suisse Group AGReiterated RatingHold$481.00View Rating Details
3/17/2016SunTrust Banks Inc.Lower Price TargetNeutral$450.00 -> $410.00View Rating Details
3/15/2016GabelliInitiated CoverageBuy$574.00View Rating Details
3/13/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
2/11/2016Bank of America Corp.Reiterated RatingBuy$649.00 -> $525.00View Rating Details
2/10/2016Royal Bank Of CanadaReiterated RatingOutperform$676.00 -> $668.00View Rating Details
2/10/2016Barclays PLCLower Price TargetEqual Weight$610.00 -> $425.00View Rating Details
8/31/2015Raymond James Financial Inc.Initiated CoverageOutperform$615.00View Rating Details
8/6/2015ArgusBoost Price TargetBuy$560.00 -> $660.00View Rating Details
8/4/2015Deutsche Bank AGReiterated RatingBuy$650.00 -> $720.00View Rating Details
7/27/2015BMO Capital MarketsReiterated RatingMarket Perform$381.00 -> $494.00View Rating Details
7/22/2015Northland SecuritiesInitiated CoverageMarket Perform$560.00View Rating Details
10/2/2014GuggenheimInitiated CoverageBuy$432.00View Rating Details
(Data available from 8/25/2014 forward)


Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)
Current Year EPS Consensus Estimate: $10.95 EPS
Next Year EPS Consensus Estimate: $14.43 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.47$2.49$1.98
Q2 20161$1.62$1.62$1.62
Q3 20161$1.69$1.69$1.69
Q4 20162$1.77$2.79$2.28
(Data provided by Zacks Investment Research)


Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.00View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.00View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.01View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.00View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.00View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.32View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.45View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.00View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.17View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.00View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.00View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.00View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.05View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.58View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.00View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.16View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.20View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.84View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.71View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.00View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.50View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.36View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.93View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.00View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.83View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.16View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.09View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.00View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.00View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateHeadline logoRegeneron ranks as one of most innovative companies by Forbes (NASDAQ:REGN) - August 24 at 6:48 PM logoRegeneron Pharmaceuticals Inc (REGN) Just Reached a Critical Fork in the Road (NASDAQ:REGN) - August 24 at 10:45 AM logoRegeneron Stock Up on BARDA Deal for MERS Antibodies (NASDAQ:REGN) - August 23 at 11:35 AM logoCompany Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc Announces ... (NASDAQ:REGN) - August 22 at 6:59 PM logoETF’s with exposure to Regeneron Pharmaceuticals, Inc. : August 22, 2016 (NASDAQ:REGN) - August 22 at 6:59 PM logoEarnings Surprise In Focus: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Investor Newswire (NASDAQ:REGN) - August 22 at 11:42 AM logoCompany Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc Announces Agreement with BARDA for the ... - Smarter Analyst (NASDAQ:REGN) - August 22 at 11:42 AM logoRegeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus (NASDAQ:REGN) - August 22 at 11:42 AM logo8:31 am Regeneron Pharma announces agreement with the BARDA to manufacture and study two antibody therapies for the potential prevention and treatment of Middle East Respiratory Syndrome (NASDAQ:REGN) - August 22 at 11:42 AM
News IconStock Spotlight: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Direction Update - Post News (NASDAQ:REGN) - August 19 at 10:01 AM logoBiotech Sales Growth: How Much Is Demand? How Much Is Price? (NASDAQ:REGN) - August 19 at 10:01 AM
News IconTop Gainers of the Day: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) from Biotechnology (NASDAQ:REGN) - August 16 at 7:12 PM logoRegeneron Pharmaceuticals Inc: Profit In REGN Stock's Pullback - (NASDAQ:REGN) - August 15 at 7:30 PM logoRegeneron Pharmaceuticals Inc: Profit In REGN Stock’s Pullback (NASDAQ:REGN) - August 15 at 11:22 AM logoThe Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen (NASDAQ:REGN) - August 12 at 10:18 AM logoRegeneron Pharmaceuticals, Inc. (REGN) - Financial and Strategic SWOT Analysis Review - New Market Research Report (NASDAQ:REGN) - August 11 at 7:37 PM logoAdverum (ADVM) Reports Narrower-than-Expected Q2 Loss (NASDAQ:REGN) - August 11 at 10:23 AM logoRegeneron Pharmaceuticals Inc.'s Q2 Earnings -- It's Still All About Eylea, but Not for Too Much Longer (NASDAQ:REGN) - August 10 at 8:10 AM logoRegeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:REGN) - August 9 at 7:23 PM logoMitsubishi Ufj Kokusai Asset Management Ltd. Lowers stake in Regeneron Pharmaceuticals Inc (REGN) (NASDAQ:REGN) - August 9 at 10:16 AM logoWhat Do Analysts Recommend for Regeneron after 2Q16 Earnings? (NASDAQ:REGN) - August 9 at 10:16 AM
News IconIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a large market cap stock a smart buy? (NASDAQ:REGN) - August 8 at 7:19 PM logoHow Did Regeneron’s Revenue and Earnings Look in 2Q16? (NASDAQ:REGN) - August 8 at 7:19 PM logoHow Did Regeneron Perform in 2Q16? (NASDAQ:REGN) - August 8 at 7:19 PM
News IconEarnings Trends of the Stocks: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), McKesson Corporation (NYSE:MCK) - News Oracle (NASDAQ:REGN) - August 8 at 11:48 AM logoRegeneron Pharmaceuticals Inc. (REGN) is Trading Lower on Unusual Volume for August 04 - (NASDAQ:REGN) - August 6 at 7:06 PM logoBaird Downgrades Rating On Regeneron Pharmaceuticals, Inc. (REGN) - Finance Daily (NASDAQ:REGN) - August 5 at 7:20 PM
News IconInfluential Analyst Rating Changes: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Symantec Corporation ... - TWN (NASDAQ:REGN) - August 5 at 7:20 PM logoRegeneron Pharmaceuticals Inc (REGN): Analyst Points Two Key Growth Drivers; Sees Over 19% Upside - TCC (NASDAQ:REGN) - August 5 at 7:20 PM logoRegeneron: The Downside of High Expectations (NASDAQ:REGN) - August 5 at 7:20 PM logoRegeneron Pharmaceuticals Inc (REGN): Analyst Points Two Key Growth Drivers; Sees Over 19% Upside (NASDAQ:REGN) - August 5 at 10:06 AM logoRegeneron Pharma downgraded by Robert W. Baird (NASDAQ:REGN) - August 5 at 10:06 AM logoWhy Regeneron Pharmaceuticals Rallied 18.6% in July (NASDAQ:REGN) - August 5 at 7:55 AM logoAnalyst Update: Regeneron Pharmaceuticals Inc, Scotts Miracle-Gro Co, and Metlife Inc (NASDAQ:REGN) - August 4 at 7:34 PM
News IconUpdate on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for the day (NASDAQ:REGN) - August 4 at 7:34 PM logoStock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:REGN) - August 4 at 7:34 PM logoKeep Calm and Spend On, Regeneron (NASDAQ:REGN) - August 4 at 7:34 PM logo[$$] Regeneron's Revenue Jumps on Sales of Eye Treatment Eylea (NASDAQ:REGN) - August 4 at 7:34 PM logoRegeneron Stock Dips As Earnings Beat And Revenue Lags (NASDAQ:REGN) - August 4 at 7:34 PM logoRegeneron Pharmaceuticals Revenue Jumps on Eye-Disease Drug (NASDAQ:REGN) - August 4 at 10:16 AM logoRegeneron revenue boosted by eye-disease drug (NASDAQ:REGN) - August 4 at 10:16 AM logoQ2 2016 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open (NASDAQ:REGN) - August 4 at 10:16 AM logoREGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:REGN) - August 4 at 10:16 AM logoEylea sales lift Regeneron's profit past estimates (NASDAQ:REGN) - August 4 at 10:16 AM logoRegeneron (REGN) Beats on Q2 Earnings, Retains Eylea View (NASDAQ:REGN) - August 4 at 10:16 AM logoThe Market In 5 Minutes: Bank Of England Cut Interest Rates For The First Time In 7 Years (NASDAQ:REGN) - August 4 at 10:16 AM logoAnalyst's Noticeable Buzzers: Heat Biologics, Inc. (NASDAQ:HTBX ... - Street Updates (NASDAQ:REGN) - August 3 at 7:27 PM logo3 Big Stock Charts for Wednesday: Regeneron Pharmaceuticals Inc (REGN), Biogen Inc (BIIB) and Dun & Bradstreet ... - (NASDAQ:REGN) - August 3 at 7:27 PM logo3 Big Stock Charts for Wednesday: Regeneron Pharmaceuticals Inc (REGN), Biogen Inc (BIIB) and Dun & Bradstreet Corp (DNB) (NASDAQ:REGN) - August 3 at 10:30 AM logoStock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Adicet Bio Announce Strategic Collaboration to ... - Smarter Analyst (NASDAQ:REGN) - August 3 at 10:21 AM


Regeneron Pharmaceuticals (NASDAQ:REGN) Chart for Thursday, August, 25, 2016

Last Updated on 8/25/2016 by Staff